Navigation Links
Alma Lasers Announces FDA Clearance of the Harmony(XL) Multi-Application System at THE Aesthetic Show 2008
Date:5/29/2008

Innovative Technology Offers Patients 60 Different Medical and Aesthetic

Treatments

LAS VEGAS, May 29 /PRNewswire/ -- Alma Lasers Ltd. ("Alma Lasers"), a global developer and marketer of laser, light, and radiofrequency based aesthetic devices, announced today at THE Aesthetic Show 2008 FDA clearance for its Harmony(XL), the newest platform for multiple aesthetic laser and light treatments. The Harmony(XL) can be used to treat more than 60 popular aesthetic indications and applications, including acne, skin rejuvenation, hair removal, varicose veins, stretch marks, tattoo removal, wrinkles and skin tightening.

The Harmony(XL) device is the most comprehensive and versatile platform to enter the medical and aesthetic industry, as it is the first to combine lasers, pulsed light, near-infrared, LED and UVB technologies with multiple exchangeable handpieces to ensure easy and effective singular and combined therapeutic treatment. The Harmony(XL) also accommodates new versions of Alma's unique Advanced Fluorescence Technology (AFT) and several different laser technologies. Compared to its successful predecessor, Harmony(XL) delivers higher energy and is the first Harmony model to incorporate Alma's proprietary IN-Motion(TM) technology, which delivers effective energy with virtually no discomfort over a range of applications. Additionally, the Harmony(XL) exclusively offers high-power Pixel(R) 2940 technology -- a breakthrough for fractionated skin resurfacing treatments.

"The FDA clearance of the Harmony(XL) reinforces Alma Lasers' commitment to developing and marketing innovative treatments for patients with every skin type and skin concern," said Howard Kelly, CEO of Alma Lasers. "While other systems in the market claim versatility by merging technologies or providing multiple handpieces, no other aesthetic system offers as many combined treatment possibilities and performance as the Harmony(XL)."

Every
'/>"/>

SOURCE Alma Lasers
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Lumenis Sues Alma Lasers and its 4 founders for 200 Million Shekels
2. Alma(TM) Lasers to Debut Five New Products at the 66th Annual Meeting of the American Academy of Dermatology
3. Alma Lasers Announces Proposed Initial Public Offering
4. Alma Lasers Answers Lumenis Complaint
5. Darwin Announces Creation of New Health Care and Errors and Omissions Divisions
6. Alseres Pharmaceuticals, Inc. Announces 2008 Annual Stockholders Meeting
7. Ekahau Announces Compatibility With 802.11n
8. Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (terlipressin) for the Treatment of Hepatorenal Syndrome Type 1
9. DRAXIS Announces Completion of Sale to Jubilant
10. WellPoint Announces Realignment of Operations, Technology and Government Services Unit
11. Hill-Rom Announces Third Quarter 2008 Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)... BOSTON, Nov. 21 Innerscope Resea... firm specializing in Emotional Response Measureme...utives who will strengthen the,company,s research...,initiatives. , The three appointments, who...de Geoffrey Gill as Chief Financial Officer and Vi...
(Date:11/21/2008)... , COLD SPRING HARBOR, N.Y. (Nov. 21, 2008) Ho...What can the lamprey immune system tell us about e...ations help with efforts to conserve rare species?...duction, and hereditary diseases? Will studies of... , To answer these and other questions in biolog...
(Date:11/21/2008)... WASHINGTON, Nov. 21 New inventio... with a variety of cognitive disabilities lead ful...ience(R) Corporation. Zimman,presented today at t...ington,DC, a meeting organized by The National C...tion to assist people with disabilities. , ...
(Date:11/21/2008)... Winter viruses may be to blame, study suggests ...The season of a baby,s birth may help predict that..., Babies born in autumn -- about four months befo...a 30 percent increased risk of asthma compared to ...study in the first December issue of the American...
Breaking Medicine News(10 mins):Health News:Innerscope Research Strengthens Management Team With Three Executive Appointments 2Health News:A new world of research possibilities with 'Emerging Model Organisms' 2Health News:New Applications for Cognitive Training 2Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3
...s of vitamin C notwithstanding, British researcher...! It is now said that vitamin C reverses pre eclam...e leading contributors to complications in childbi...n lead onto eclampsia which, when left untreated, ...
...hat causes infectious mononucleosis, Epstein-Barr ...o the development of Hodgkin's disease. But no one...BV and Hodgkin's survival, according to researcher... from Northern California Cancer Center in Union C...
...d on more than 1600 women reveals that parathyroid...ne density and cut the risk of fractures in them. ...ium levels in the body. The new aspect of th...ures has opened up the prospect of the hormone bei...
...n from Mayo Foundation in Rochester, Minnesota has...ble metal stents in the digestive tract of people ...ese patients commonly suffer from obstructions and...ke difficulty in swallowing, if the block is in th...
Other Medicine News:
(Date:11/21/2008)... -- Ikaria Holdings, Inc. today announced that it ...New Jersey Technology Council (NJTC), a 1,200-memb...support, networking opportunities, information and...rs. Ikaria earned the award based on criteria incl... provision. , , "We are delighted that the ...
(Date:11/20/2008)...ire/ -- New Jersey American Water has lifted the ...rs in the following municipalities in Middlesex, S...ounty , , , Dunellen , Ediso...South Plainfield , , , , Somerset C...idgewater , Green Brook , Hillsborou...
(Date:11/20/2008)...20 Arpida (SWX:,ARPN) a...ory Committee of the,U.S. Food and Drug Administr...l of intravenous iclaprim, an antibiotic currently...h complicated skin and skin structure infections,...sistant Staphylococcus,aureus (MRSA). , Ar...
(Date:11/20/2008)...re-FirstCall/ -- Duska Therapeutics,Inc., (OTC B...submitted its,pivotal Phase 3 ATPace clinical tri...ssessment (SPA) procedure with the U.S. Food and D...uring an agreement with the FDA, Duska intends to ...cebo-controlled and randomized Phase 3,clinical t...
Breaking Medicine Technology:Ikaria(R) Named Private Company of the Year by New Jersey Technology Council 2New Jersey American Water Lifts Precautionary Boil Water Advisory For Middlesex, Somerset and Union Counties 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 2Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 3Arpida Comments on FDA's Anti-infective Drugs Advisory Committee Outcome 4Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 2Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 3Duska Therapeutics Applies for Phase 3 Special Protocol Assessment 4Mindray to Attend 2007 RSNA Conference in Chicago 6781 1Mindray to Attend 2007 RSNA Conference in Chicago 6781 2Mindray to Attend 2007 RSNA Conference in Chicago 6781 3Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 6779 1Genomic Health to Present at 19th Annual Piper Jaffray Health Care Conference 6779 2Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 1Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 2Eclipsys to Present at the Merrill Lynch Health Services Investor Conference 6777 3Danaher Closes Subsequent Offering Period for Tektronix 3B Acquires Over 90 25 of TEK Shares 6775 1Danaher Closes Subsequent Offering Period for Tektronix 3B Acquires Over 90 25 of TEK Shares 6775 2
...s TNF-alpha Production Through Inhibition,of PDE-4...ire/ -- Anacor,Pharmaceuticals, a privately held p... from its placebo-controlled Phase 1 trial of,AN27...gation for,the treatment of psoriasis. The trial s...omparable to existing topical,treatments for psori...
...k, June 06, 2007 /PRNewswire-FirstCall/,-- XTL Bio...ompleted the analysis of results from a Phase I cl...c Hepatitis C. This Phase I,trial was a placebo co... evaluated the safety, tolerability and antiviral ... The study enrolled 56,patients into seven cohorts...
Other Medicine Technology:Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory,Compound, Shows Efficacy in Psoriasis 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 2XTL Provides Update on Phase I Clinical Trial of XTL-2125 3
Inquire
...are is easy to configure for gravimetric calibrati...ndard method or enter your own parameters (number ... QualiTrace automatically manages the calibration ...from the balance to the software, which establishe...
Reservoir, Low Profile, Single Well, Flat Bottom, 90mL Available Sterile
Reagent Basin, 60mL, 5/Box
Medicine Products: